A Novel Expression Signature from the Perspective of Mesenchymal-Epithelial Transition for Hepatocellular Carcinoma with Regard to Prognosis, Clinicopathological Features, Immune Cell Infiltration, Chemotherapeutic Efficacy, and Immunosuppressive Molecules

<div>Development of a MRGs expression signature in the TCGA dataset. (a) The Kaplan–Meier curve survival analysis. (b) The risk score curve plot and risk score scatter plot of high- and low-risk HCC patients. (c) PCA plot of the TCGA dataset. (d) t-SNE analysis of the TCGA dataset. (e) AUC of time-dependent ROC used to assess performance of this signature in predictive ability. (f) AUC of this signature and clinicopathological parameters.</div>

Journal of Oncology

fig2

Figure 2

Figure 2: A Novel Expression Signature from the Perspective of Mesenchymal-Epithelial Transition for Hepatocellular Carcinoma with Regard to Prognosis, Clinicopathological Features, Immune Cell Infiltration, Chemotherapeutic Efficacy, and Immunosuppressive Molecules 

Figure 2 | A Novel Expression Signature from the Perspective of Mesenchymal-Epithelial Transition for Hepatocellular Carcinoma with Regard to Prognosis, Clinicopathological Features, Immune Cell Infiltration, Chemotherapeutic Efficacy, and Immunosuppressive Molecules 